Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 3Phase 1/2 3Phase 1 2Phase NA 1

Status

Terminated 10Completed 10Unknown 6Recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 2Solid Tumors Refractory to Standard Therapy 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Sunitinib × Clear all
NCT06222593 2026-04-01

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

State University of New York at Buffalo

Phase 1/2 Recruiting
28 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

3D Medicines

Phase 1/2 Recruiting
170 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT06940349 2025-04-23

COPS-01

Rabin Medical Center

Phase 1/2 Recruiting
100 enrolled
Other solid neoplasm

Solid Tumors Refractory to Standard Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡